Thousand Oaks, California, September 3, 2025

News Summary

Amgen, a leading biotechnology company, plans to invest $600 million in a new research and development center in Thousand Oaks, California. The groundbreaking is set for Q3 of this year, focusing on next-generation drug discovery rather than manufacturing. This expansion aligns with Amgen’s strategy to enhance U.S. domestic research capabilities amidst rising supply chain pressures. The facility will foster collaboration among researchers and reflects a broader trend in the pharmaceutical industry to increase investments in the U.S.

California

Amgen, a leading biotechnology company, is set to invest $600 million in a new research and development facility located in Thousand Oaks, California. Groundbreaking for the center is expected to occur in the third quarter of the year. This facility aims to bring together Amgen’s researchers, engineers, and scientists to enhance collaboration and accelerate the process of next-generation drug discovery.

The new center will not function as a drug manufacturing site but will instead provide advanced tools and resources necessary for scientific discovery. This strategic move is part of Amgen’s broader initiative to respond to U.S. import tariffs and ongoing supply chain pressures by increasing domestic research and production capabilities.

Headquartered in Thousand Oaks, Amgen owns nearly 2 million square feet of biotechnology space within the Conejo Valley, located approximately 40 miles west of Los Angeles. This expansion aligns with a recent trend in the pharmaceutical industry, where companies are looking to bolster their operations in the United States. According to commercial real estate firm JLL, 15 major drugmakers plan to invest over $270 billion in U.S. projects in 2025, marking a significant 185% increase in demand for biomanufacturing.

To keep pace with this demand, Alexandria Real Estate Equities has also recently introduced more than 500,000 square feet of lab space in the first half of this year, with additional projects in development. Amgen has previously announced substantial expansions for its manufacturing operations, including a $900 million enhancement in Columbus, Ohio, and a $1 billion investment in a new manufacturing site in Holly Springs, North Carolina.

The Food and Drug Administration (FDA) has developed a new program aimed at streamlining the approval process for new drug manufacturing sites in the country, which will further facilitate these investments. In addition, the White House is actively working to reduce the construction timelines for pharmaceutical facilities, which currently can take up to 10 years to complete.

Amgen attributes its investment strategy in part to the Tax Cuts and Jobs Act of 2017, which has provided significant incentives for domestic investments. The company anticipates that forthcoming legislation will continue to support such growth, contributing to stronger U.S. drug supply chains and enhancing domestic scientific research and innovation.

This expansion comes at a time when other major pharmaceutical companies, including AstraZeneca, Eli Lilly, Sanofi, and Novartis, have also recently announced substantial investments in the United States. This trend supports ongoing policies that encourage the reshoring of pharmaceutical production back to American soil, addressing growing concerns about dependency on foreign sources within the healthcare sector.

Key Highlights of Amgen’s New Facility

• Investment Amount: $600 million
• Location: Thousand Oaks, California
• Size: Bringing researchers and scientists under one roof for collaboration
• Focus: Next-generation drug discovery, not drug manufacturing
• Headquarters: Amgen’s main base in Thousand Oaks with nearly 2 million square feet of biotech space
• Impact: Part of a larger trend of over $270 billion investment in U.S. drug manufacturing by major companies

FAQ

Chart: Key Features of Amgen’s New Facility

Deeper Dive: News & Info About This Topic

• Fierce Biotech
• Wikipedia: Amgen
• CNBC
• Google Search: Amgen investment research facility
• BioPharma Dive
• Encyclopedia Britannica: biotechnology
• CoStar
• Google News: Amgen expansion California
• Business Facilities
• Google Scholar: next-generation drug discovery
• Reuters
• Google Search: Amgen domestic research investments

Author: STAFF HERE SAN DIEGO WRITER

SAN DIEGO STAFF WRITER The SAN DIEGO STAFF WRITER represents the experienced team at HERESanDiego.com, your go-to source for actionable local news and information in San Diego, San Diego County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Comic-Con International, San Diego County Fair, and San Diego Pride Festival. Our coverage extends to key organizations like the San Diego Regional Chamber of Commerce and United Way of San Diego County, plus leading businesses in biotechnology, healthcare, and technology that power the local economy such as Qualcomm, Illumina, and Scripps Health. As part of the broader HERE network, including HEREAnaheim.com, HEREBeverlyHills.com, HERECostaMesa.com, HERECoronado.com, HEREHollywood.com, HEREHuntingtonBeach.com, HERELongBeach.com, HERELosAngeles.com, HEREMissionViejo.com, and HERESantaAna.com, we provide comprehensive, credible insights into California's dynamic landscape.